Inhibrx Biosciences, Inc.
Lappe Mark (Chief Executive Officer) purchased 10,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $99.88 ($98.87–$101.70, $1.00M total) across 4 trades over 2026-09-25 to 2026-09-28.
Inhibrx Biosciences reported that its experimental cancer drug INBRX-106, combined with Merck's Keytruda, achieved a 48.3% response rate in a Phase 2 study, nearly double Keytruda's 26.5% alone. The stock fell 8.8% to $110.45 despite the positive data, with the company planning to expand the study for HPV-positive patients, according to Reuters.
CapsoVision (CV) director bought $9.9M shares at $5.69 each. Corebridge (CRBG) 10% owner Nippon Life bought $7.47M shares at $35.08. Inhibrx (INBX) director bought $500K shares at $100. Diamondback (FANG) director sold $15.32M shares at $204.31. Arista (ANET) CTO sold $8.82M shares near 52-week high. Duolingo (DUOL) CEO sold $6.17M shares at $150-$152. Asana (ASAN) CEO sold $4.2M shares. Robinhood (HOOD) CEO sold $32.55M shares.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning INBX (Inhibrx Biosciences, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent INBX coverage spans insider activity, financial news and technology.
In the last 30 days, INBX insiders filed 19 SEC Form 4 transactions — 14 purchases ($5.5M) and 5 sales ($279K). The most active reporter was Lappe Mark, Chief Executive Officer, with 10 filings.
The insider purchase suggests confidence from management and may create modest buying pressure.
Positive trial data de‑risk the program but the unexpected price decline suggests short‑term sell pressure.
Small insider buy, limited market impact.
A sizable insider purchase may signal confidence and could support short-term price upside.
Minimal effect on price; likely unnoticed by market.
AlphAI scores every news story that mentions INBX with an AI model for sentiment and relevance, and aggregates insider trades from Inhibrx Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lappe Mark (Chief Executive Officer) purchased 10,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $99.88 ($98.87–$101.70, $1.00M total) across 4 trades over 2026-09-25 to 2026-09-28.
1 min readInhibrx Biosciences reported that its experimental cancer drug INBRX-106, combined with Merck's Keytruda, achieved a 48.3% response rate in a Phase 2 study, nearly double Keytruda's 26.5% alone. The stock fell 8.8% to $110.45 despite the positive data, with the company planning to expand the study for HPV-positive patients, according to Reuters.
3 min readCapsoVision (CV) director bought $9.9M shares at $5.69 each. Corebridge (CRBG) 10% owner Nippon Life bought $7.47M shares at $35.08. Inhibrx (INBX) director bought $500K shares at $100. Diamondback (FANG) director sold $15.32M shares at $204.31. Arista (ANET) CTO sold $8.82M shares near 52-week high. Duolingo (DUOL) CEO sold $6.17M shares at $150-$152. Asana (ASAN) CEO sold $4.2M shares. Robinhood (HOOD) CEO sold $32.55M shares.
2 min readKayyem Jon Faiz purchased 5,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at $100.00 ($0.50M total) on 2026-09-23.
1 min readOn September 15-16, 2026, insiders made notable transactions: Avenue RP Opportunities Fund and director Par Chadha bought XBP Global Holdings (XBP) shares at $2.83 each, totaling $1.5M and $580K respectively. Directors at Agree Realty (ADC) bought shares near its 52-week low. A director at Inhibrx (INBX) bought 5K shares at $100 each. A director at CrowdStrike (CRWD) sold 119K shares for $28.6M. Silver Lake Partners sold Dell (DELL) shares for $28M. A 10% owner of Talos Energy (TALO) sold 1.38M
2 min readKayyem Jon Faiz purchased 5,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at $100.00 ($0.50M total) on 2026-09-16.
1 min readMANHARD KIMBERLY sold 1,500 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $109.03 ($105.05–$111.78, $0.16M total) across 3 trades over 2026-09-11 to 2026-09-15.
1 min readMANHARD KIMBERLY sold 1,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $115.47 ($115.14–$115.80, $0.12M total) across 2 trades over 2026-09-08 to 2026-09-09.
1 min readOn September 9, 2026, significant insider trading activity was reported. Alumis Inc. (ALMS) director acquired $10.7M in shares, while NVIDIA (NVDA) director sold $235.6M. Greenwave (GWAV) CEO bought $8M in shares, and BELITE BIO (BLTE) executives sold $31.9M. Workday (WDAY) director sold $17.9M in shares. Dell (DELL) insiders sold $48.1M. Inhibrx (INBX) and Cytosorbents (CTSO) directors also made notable purchases.
3 min readKayyem Jon Faiz purchased 5,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at $113.52 ($0.57M total) on 2026-09-08.
1 min read
